Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
None (1) ·
Agomelatine (1) ·
Amoxapine (1) ·
Brivaracetam (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fosphenytoin (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Lacosamide (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Perampanel (1) ·
Phenelzine (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Rufinamide (1) ·
Sertraline (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
None (1) ·
Anafranil (1) ·
Aptiom (1) ·
Aurorix (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Edronax (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fetzima (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Ludiomil (1) ·
Luminal (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Onfi (1) ·
Parnate (1) ·
Rexulti (1) ·
Sabril (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vimpat (1) ·
Vivactil (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zoloft (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin releaser; sigma-1 agonist (1) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (37) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
legal:
Showing below up to 39 results in range #1 to #39.